Adrian Towse
Names
first: |
Adrian |
last: |
Towse |
Identifer
Contact
Affiliations
-
Office of Health Economics
Research profile
author of:
- An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment
Policy Papers, Center for Global Development (2022)
by Adrian Towse & Rachel Silverman Bonnifield
(ReDIF-paper, cgd:ppaper:277) - Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
Health Policy, Elsevier (2017)
by Towse, Adrian & Hoyle, Christopher K. & Goodall, Jonathan & Hirsch, Mark & Mestre-Ferrandiz, Jorge & Rex, John H.
(ReDIF-article, eee:hepoli:v:121:y:2017:i:10:p:1025-1030) - Is disease management relevant in Europe: some evidence from the United Kingdom
Health Policy, Elsevier (1999)
by Mason, Anne & Drummond, Michael & Towse, Adrian
(ReDIF-article, eee:hepoli:v:48:y:1999:i:1:p:69-77) - Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
NBER Working Papers, National Bureau of Economic Research, Inc (2011)
by Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse
(ReDIF-paper, nbr:nberwo:17174) - Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
NBER Working Papers, National Bureau of Economic Research, Inc (2012)
by Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz
(ReDIF-paper, nbr:nberwo:18593) - Unknown item RePEc:ohe:briefg:000075 (paper)
- The Market for Biosimilars: Evolution and Policy Options
Briefing, Office of Health Economics (2008)
by Deven Chauhan;Jorge Mestre-Ferrandiz;Adrian Towse
(ReDIF-paper, ohe:briefg:000238) - Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds
Briefing, Office of Health Economics (2006)
by Martin Buxton;Adrian Towse
(ReDIF-paper, ohe:briefg:000267) - Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
Briefing, Office of Health Economics (1997)
by Martin Cave;Adrian Towse
(ReDIF-paper, ohe:briefg:000427) - From Efficacy to Cost-Effectiveness
Briefing, Office of Health Economics (1998)
by Michael F. Drummond;Adrian Towse
(ReDIF-paper, ohe:briefg:000438) - Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?
Briefing, Office of Health Economics (2003)
by Paul Fenn;Alastair Gray;Neil Rickman;Rodrigo Salinas;Adrian Towse
(ReDIF-paper, ohe:briefg:000484) - How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
Briefing, Office of Health Economics (2016)
by Amanda Cole;Adrian Towse;Michelle Mujoomdar;Arnold Chan;Franz Pichler
(ReDIF-paper, ohe:briefg:001740) - Unknown item RePEc:ohe:briefg:001835 (paper)
- Unknown item RePEc:ohe:briefg:001836 (paper)
- Unknown item RePEc:ohe:briefg:001837 (paper)
- Unknown item RePEc:ohe:briefg:001838 (paper)
- Incentives for New Drugs to Tackle Anti-Microbial Resistance
Briefing, Office of Health Economics (2017)
by Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz
(ReDIF-paper, ohe:briefg:001842) - Unknown item RePEc:ohe:briefg:001851 (paper)
- Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
Briefing, Office of Health Economics (2017)
by Margherita Neri;Adrian Towse
(ReDIF-paper, ohe:briefg:001922) - Unknown item RePEc:ohe:conrep:000050 (paper)
- Unknown item RePEc:ohe:conrep:000192 (paper)
- Unknown item RePEc:ohe:conrep:000212 (paper)
- Unknown item RePEc:ohe:conrep:000234 (paper)
- Unknown item RePEc:ohe:conrep:000265 (paper)
- Unknown item RePEc:ohe:conrep:001660 (paper)
- Unknown item RePEc:ohe:conrep:001699 (paper)
- Unknown item RePEc:ohe:conrep:001743 (paper)
- Unknown item RePEc:ohe:conrep:001748 (paper)
- Unknown item RePEc:ohe:conrep:001784 (paper)
- Unknown item RePEc:ohe:conrep:001802 (paper)
- Unknown item RePEc:ohe:conrep:001944 (paper)
- Unknown item RePEc:ohe:conrep:001978 (paper)
- The R&D Cost of a New Medicine
Monograph, Office of Health Economics (2012)
by Jorge Mestre-Ferrandiz;Jon Sussex;Adrian Towse
(ReDIF-paper, ohe:monogr:000135) - New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
Monograph, Office of Health Economics (2011)
by Priya Sharma;Adrian Towse
(ReDIF-paper, ohe:monogr:000184) - Biosimilars: How Much Entry and Price Competition Will Result?
Monograph, Office of Health Economics (2010)
by Adrian Towse;Nancy Mattison;Jorge Mestre-Ferrandiz
(ReDIF-paper, ohe:monogr:000195) - Unknown item RePEc:ohe:monogr:000242 (paper)
- Economic Post-Launch Studies: Matching the Desirable with the Feasible
Monograph, Office of Health Economics (2006)
by Anne R. Mason;Michael F. Drummond;Adrian Towse
(ReDIF-paper, ohe:monogr:000268) - Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS
Monograph, Office of Health Economics (1995)
by Adrian Towse
(ReDIF-paper, ohe:monogr:000409) - Industrial Policy and the Pharmaceutical Industry
Monograph, Office of Health Economics (1995)
by Adrian Towse
(ReDIF-paper, ohe:monogr:000414) - Value of the Pharmaceutical Industry to the UK Economy
Monograph, Office of Health Economics (1995)
by David Hale;Adrian Towse
(ReDIF-paper, ohe:monogr:000415) - Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?
Monograph, Office of Health Economics (1997)
by Adrian Towse
(ReDIF-paper, ohe:monogr:000423) - Disease Management, the NHS and the Pharmaceutical Industry
Monograph, Office of Health Economics (1999)
by Anne R. Mason;Michael F. Drummond;Adrian Towse
(ReDIF-paper, ohe:monogr:000446) - Cost-Effectiveness Thresholds: Economic and ethical issues
Monograph, Office of Health Economics (2002)
by Clive Pritchard;Nancy Devlin;Adrian Towse
(ReDIF-paper, ohe:monogr:000473) - Influencing Prescribing in a Primary Care Led NHS
Monograph, Office of Health Economics (2002)
by Anne R. Mason;Michael F. Drummond;Jonathan Cooke;Adrian Towse
(ReDIF-paper, ohe:monogr:000476) - Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty
Monograph, Office of Health Economics (2002)
by Hannah Kettler;Adrian Towse
(ReDIF-paper, ohe:monogr:000479) - Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
Occasional Paper, Office of Health Economics (2013)
by Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex
(ReDIF-paper, ohe:occpap:000106) - The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
Occasional Paper, Office of Health Economics (2012)
by Lou Garrison;Ruth Puig-Peiro;Adrian Towse
(ReDIF-paper, ohe:occpap:000167) - Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
Occasional Paper, Office of Health Economics (2011)
by Patricia Danzon;Martina Garau;Adrian Towse
(ReDIF-paper, ohe:occpap:000191) - New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
Occasional Paper, Office of Health Economics (2010)
by Priya Sharma;Adrian Towse
(ReDIF-paper, ohe:occpap:000216) - Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
Occasional Paper, Office of Health Economics (2014)
by Adrian Towse
(ReDIF-paper, ohe:occpap:001561) - Unknown item RePEc:ohe:occpap:001600 (paper)
- Unknown item RePEc:ohe:respap:000037 (paper)
- Unknown item RePEc:ohe:respap:000160 (paper)
- Unknown item RePEc:ohe:respap:000177 (paper)
- Unknown item RePEc:ohe:respap:000188 (paper)
- Unknown item RePEc:ohe:respap:000211 (paper)
- Unknown item RePEc:ohe:respap:001764 (paper)
- Unknown item RePEc:ohe:respap:001811 (paper)
- Unknown item RePEc:ohe:respap:001848 (paper)
- Unknown item RePEc:ohe:respap:001997 (paper)
- Unknown item RePEc:ohe:respap:001998 (paper)
- Multi-indication Pricing: Pros, Cons and Applicability to the UK
Seminar Briefing, Office of Health Economics (2015)
by Jorge Mestre-Ferrandiz;Renato Dellamano;Michele Pistollato;Adrian Towse
(ReDIF-paper, ohe:sembri:001653) - Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
Oxford Review of Economic Policy, Oxford University Press (2016)
by Mikel Berdud & Adrian Towse & Hannah Kettler
(ReDIF-article, oup:oxford:v:32:y:2016:i:1:p:64-87.) - Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) (2012)
by Michael Drummond & Adrian Towse
(ReDIF-article, spr:eujhec:v:13:y:2012:i:1:p:1-5) - Orphan drugs policies: a suitable case for treatment
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) (2014)
by Michael Drummond & Adrian Towse
(ReDIF-article, spr:eujhec:v:15:y:2014:i:4:p:335-340) - Genetic screening, health care and the insurance industry
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) (2004)
by Diego Ossa & Adrian Towse
(ReDIF-article, spr:eujhec:v:5:y:2004:i:2:p:116-121) - The desirability and feasibility of economic studies of drugs post-launch
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) (2006)
by Michael Drummond & Anne Mason & Adrian Towse
(ReDIF-article, spr:eujhec:v:7:y:2006:i:1:p:5-6) - Operationalizing Value-Based Pricing of Medicines
PharmacoEconomics, Springer (2013)
by Jon Sussex & Adrian Towse & Nancy Devlin
(ReDIF-article, spr:pharme:v:31:y:2013:i:1:p:1-10) - Biosimilars: How Can Payers Get Long-Term Savings?
PharmacoEconomics, Springer (2016)
by Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud
(ReDIF-article, spr:pharme:v:34:y:2016:i:6:d:10.1007_s40273-015-0380-x) - Incentives for R&D for New Antimicrobial Drugs
International Journal of the Economics of Business, Taylor & Francis Journals (2011)
by Adrian Towse & Priya Sharma
(ReDIF-article, taf:ijecbs:v:18:y:2011:i:2:p:331-350) - European Union Pharmaceutical Markets: A Case for Differential Pricing?
International Journal of the Economics of Business, Taylor & Francis Journals (2015)
by Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison
(ReDIF-article, taf:ijecbs:v:22:y:2015:i:2:p:263-275) - Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
Health Economics, John Wiley & Sons, Ltd. (2015)
by Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse
(ReDIF-article, wly:hlthec:v:24:y:2015:i:2:p:238-252) - Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context
Health Economics, John Wiley & Sons, Ltd. (2015)
by Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz
(ReDIF-article, wly:hlthec:v:24:y:2015:i:3:p:294-301) - The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8
Health Economics, John Wiley & Sons, Ltd. (1994)
by Adrian Towse
(ReDIF-article, wly:hlthec:v:3:y:1994:i:5:p:347-348) - Medical negligence and the NHS: an economic analysis
Health Economics, John Wiley & Sons, Ltd. (1999)
by Adrian Towse & Patricia Danzon
(ReDIF-article, wly:hlthec:v:8:y:1999:i:2:p:93-101)